Advertisement
UK markets close in 3 hours 9 minutes

  • FTSE 100

    7,835.57
    -41.48 (-0.53%)
     

  • FTSE 250

    19,304.02
    -146.65 (-0.75%)
     

  • AIM

    742.27
    -3.02 (-0.41%)
     

  • GBP/EUR

    1.1682
    -0.0001 (-0.01%)
     

  • GBP/USD

    1.2454
    +0.0015 (+0.12%)
     

  • Bitcoin GBP

    52,473.13
    +2,310.15 (+4.61%)
     

  • CMC Crypto 200

    1,337.30
    +24.67 (+1.92%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CRUDE OIL

    82.15
    -0.58 (-0.70%)
     

  • GOLD FUTURES

    2,391.60
    -6.40 (-0.27%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,720.31
    -117.09 (-0.66%)
     

  • CAC 40

    8,009.52
    -13.74 (-0.17%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Novartis says it is subject of Swiss competition probe

Reuters
FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

BERLIN (Reuters) - Novartis is the subject of an investigation by the Swiss competition commission into patent use, the Swiss pharmaceutical company said on Thursday.

"Novartis is fully cooperating with authorities and is confident to clarify legitimacy of its position," it said in a statement, adding that the opening of an investigation did not imply any wrongdoing or financial impact.

Novartis will not comment further on the investigation at this time, it added.

(Writing by Miranda Murray; Editing by Michael Shields)